A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a pharmaceutical company with a market capitalization of $22.74 million, has entered into a material definitive agreement and closed a private investment in ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Company to present pipeline update at 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- BOSTON, January 09, 2025--(BUSINESS WIRE)--Nimbus Therapeutics ...

pipeline, and anticipated milestones for 2025 and beyond at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT. Nimbus Therapeutics is a clinical-stage ...

Company to present pipeline update at 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a ...

Company to present pipeline update at 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...

Jan. 9, 2025 /PRNewswire/ -- Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of rationally designed adeno-associated virus (AAV) gene therapies for devastating ...